Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SETD1B | Q9UPS6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764958 | 0.91 | KAT6A (0.52) | KMT2AGAAMCL1LMNA | |
| SCHEMBL6769551 | 0.87 | GAA (0.51) | KMT2AALDH1A1RAB9AMEN1HPGD | |
| SCHEMBL6761561 | 0.81 | KAT6A (0.53) | KMT2AMEN1GAALMNA | |
| SCHEMBL7109395 | 0.79 | RAB9A (0.56) | KMT2AALDH1A1RAB9AMEN1HPGD | |
| SCHEMBL6763607 | 0.76 | MCL1 (0.56) | KMT2AALDH1A1MEN1GAAMCL1 | |
| SCHEMBL6764909 | 0.73 | RAB9A (0.57) | KMT2AALDH1A1RAB9AMEN1HPGD | |
| SCHEMBL11586955 | 0.72 | MCL1 (0.71) | KMT2AALDH1A1RAB9AMEN1GAA | |
| SCHEMBL10915304 | 0.72 | MCL1 (0.50) | KMT2AALDH1A1RAB9AMEN1GAA | |
| SCHEMBL6761210 | 0.69 | MCL1 (0.54) | KMT2AALDH1A1MEN1GAAMCL1 | |
| SCHEMBL7242181 | 0.69 | ALDH1A1 (0.59) | KMT2AALDH1A1RAB9ANPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730704-B2 | REACTING AN ARYLOXYPROPIONIC ACID HYDRAZIDE WITH AN ARYLSULFONYL CHLORIDE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2004-05-04 | — | — | US | disclosed |
| US-20030187065-A1 | 1-(ARYLOXY)PROPIONOYL-2-ARYLSULFONYL HYDRAZINES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS HYPOGLYCEMIC AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187065-A1 | 1-(ARYLOXY)PROPIONOYL-2-ARYLSULFONYL HYDRAZINES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS HYPOGLYCEMIC AGENTS | IAPP, DPP4, GLP1R | KMT2A 2712/4885ALDH1A1 292/4885RAB9A 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.